(LUCD) Lucid Diagnostics - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US54948X1090
LUCD: Esophageal, DNA, Test, Collection, Device
Lucid Diagnostics Inc. (NASDAQ:LUCD) is a commercial-stage medical diagnostics company specializing in early detection of esophageal precancer and cancer, primarily targeting patients with gastroesophageal reflux disease (GERD) at high risk of developing esophageal adenocarcinoma (EAC). The companys flagship product, EsoGuard, is a non-invasive esophageal DNA test, paired with the EsoCheck cell collection device, designed to identify precancerous cellular changes in at-risk GERD patients. This innovative approach aims to improve early detection rates and reduce mortality associated with EAC. Founded in 2018 and headquartered in New York, Lucid Diagnostics operates as a subsidiary of PAVmed Inc., focusing on advancing diagnostic solutions for unmet medical needs in gastroenterology. Web URL: https://www.luciddx.com
The companys technology integrates molecular biology and cytology to detect biomarkers associated with esophageal precancer and cancer. By enabling early intervention, Lucid Diagnostics addresses a critical gap in the management of GERD-related complications. Its diagnostic tools are designed to be user-friendly and minimally invasive, making them accessible for widespread clinical use. With a strong focus on improving patient outcomes, Lucid Diagnostics is positioned to play a key role in the early detection and prevention of esophageal cancer.
3-Month Forecast: Based on
Additional Sources for LUCD Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
LUCD Stock Overview
| Market Cap in USD | 131m |
| Sector | Healthcare |
| Industry | Medical Devices |
| GiC Sub-Industry | Health Care Equipment |
| IPO / Inception | 2021-10-14 |
LUCD Stock Ratings
| Growth Rating | -46.3 |
| Fundamental | - |
| Dividend Rating | 0.0 |
| Rel. Strength | 51.7 |
| Analysts | 4.67/5 |
| Fair Price Momentum | 1.02 USD |
| Fair Price DCF | - |
LUCD Dividends
No Dividends PaidLUCD Growth Ratios
| Growth Correlation 3m | 55.7% |
| Growth Correlation 12m | 55.7% |
| Growth Correlation 5y | -86.1% |
| CAGR 5y | -47.69% |
| CAGR/Max DD 5y | -0.51 |
| Sharpe Ratio 12m | 0.47 |
| Alpha | 43.85 |
| Beta | 1.342 |
| Volatility | 118.15% |
| Current Volume | 783.3k |
| Average Volume 20d | 893k |
As of April 18, 2025, the stock is trading at USD 1.21 with a total of 783,329 shares traded.
Over the past week, the price has changed by -3.20%, over one month by -17.69%, over three months by +43.57% and over the past year by +50.85%.
Probably not. Based on ValueRay Analyses, Lucid Diagnostics (NASDAQ:LUCD) is currently (April 2025) not a good stock to buy. It has a ValueRay Growth Rating of -46.26 and therefor a somwhat technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of LUCD as of April 2025 is 1.02. This means that LUCD is currently overvalued and has a potential downside of -15.7%.
Lucid Diagnostics has received a consensus analysts rating of 4.67. Therefor, it is recommend to buy LUCD.
- Strong Buy: 4
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, LUCD Lucid Diagnostics will be worth about 1.1 in April 2026. The stock is currently trading at 1.21. This means that the stock has a potential downside of -6.61%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 3.7 | 203.3% |
| Analysts Target Price | 3.5 | 189.3% |
| ValueRay Target Price | 1.1 | -6.6% |